FloodLAMP FDA Town Halls Analysis of Refusals Critical analysis of the FDA's systematic refusal to answer questions during ~100 COVID-19 Diagnostic Virtual Town Hall sessions (2020-2023), covering the "specific submissions" policy's impact on transparency and accountability. Includes an appropriateness rubric, classification and scoring of 135 identified refusal instances, and summary statistics showing an average appropriateness score of 3.1/5 for active refusals, with 32% scoring questionable or worse. ai file regulatory fda-townhalls _AI_FDA_Townhall_Analysis_of_Refusals.md regulatory/fda-townhalls/_AI_FDA_Townhall_Analysis_of_Refusals.md 2026_03_26 **AI GENERATED - MAY CONTAIN ERRORS** Created during archive preparation using AI-assisted drafting and analysis, then partially revised through human review. Critical analysis in Section 1 is substantively authored by FloodLAMP founder Randy True and was later revised with AI assistance. Sections 2-4 were developed collaboratively with AI support; Section 3 began as heuristic code-based classification and was later partially reviewed, corrected, and expanded through manual comparison against the companion compilation file. This document is not fully audited and may still contain errors, but it is no longer purely unaudited AI output. Current counts reflect 135 identified refusal instances across 90 of 100 files: 88 boilerplate opening disclaimers and 47 scored active refusals. Based on section-titles transcript files. Companion file: _compilation_fda-refusals-to-answer.md. fda, townhalls, refusals, transparency, accountability md CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/ 35637 47995 gfile-url xfile-github-download-url pdf-gdrive-url pdf-github-url github-markdown-url github-markdown-download-url web-pdf-url web-slides-url youtube-url web-url